Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Chemical or Radiation/Nuclear (CRN) Threats
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Allergy and Infectious Diseases (NIAID), under the Department of Health and Human Services, is advancing research initiatives aimed at developing new medical countermeasures and technologies to address civilian radiation and chemical threats. This effort supports the broader NIH mission by focusing on diagnosing, mitigating, and treating acute and delayed health effects resulting from radiation or chemical exposures during public health emergencies. Research administration is managed through two primary programs: the Radiation and Nuclear Countermeasures Program (RNCP) and the Chemical Countermeasures Research Program (CCRP), both of which are supported by congressional mandates. The RNCP emphasizes the development of radiation-specific models, biomarkers of damage, diagnostic devices, and therapeutics designed to improve survival and reduce injuries affecting multiple organ systems. Meanwhile, the CCRP focuses on preclinical evaluation of potential treatments that mitigate harm following exposure to government-listed Chemicals of Concern, prioritizing candidates effective in civilian mass casualty scenarios post-exposure. The legal framework for this research includes Sections 301 and 405 of the Public Health Service Act and relevant federal regulations, enabling NIAID to forecast opportunities for grant funding to support these critical countermeasure developments.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the NIH mission by supporting research on concepts and technologies to address civilian radiation or chemical threats. Research is administered by NIAID on behalf of NIH via the Radiation and Nuclear (RNCP), and the Chemical Countermeasures (CCRP) Research Programs. A shared congressional mandate to the NIH OD (119 Stat. 2850; Public Law 109-149-Dec. 30, 2005), supports research to develop new ideas and technologies to diagnose, mitigate, and treat acute and delayed effects of radiation or chemical exposures during and after a public health emergency.
RNCP: Supports development of radiation-focused models, biomarkers of damage, devices to assess and predict injury, and products to improve survival and reduce morbidity across multiple organ systems.
CCRP: Supports preclinical work on products to mitigate and treat injuries after exposure to government-designated Chemicals of Concern. Candidates with efficacy in a post-exposure, civilian mass casualty setting are sought.
Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
